Biosimilars
Provider 
Sandozsandoz.comPublic
Founded 1886
Sells To Healthcare Providers, Hospitals, Retail
Pricing Model B2B, Product Sales
Ownership Public
Sandoz pioneered biosimilars with the world's first biosimilar program in 1996 and first approval in 2006.
Biosimilars are versions of biologic medicines made from living cells, treating cancer, diabetes, arthritis and autoimmune conditions. Sandoz achieved first biosimilar approvals in Europe in 2006, Japan and Canada in 2009, and the US in 2015.
The company has 13 marketed biosimilar medicines and a pipeline of around 39 candidates across immunology, oncology, endocrinology and ophthalmology. In 2026 Sandoz unveiled its Bio100 ambition at Capital Markets Day and announced a strategic collaboration with Henlius on up to 10 biosimilars.
Biocon
Biocon — Biosimilars Portfolio
biocon.com
Bionovis
Bionovis — Biologic and Biosimilar Medicines
bionovis.com.br
Fresenius Kabi
Fresenius Kabi Brasil Biopharma
fresenius-kabi.com
| Attribute | Biosimilars | Biocon — Biosimilars Portfolio | Bionovis — Biologic and Biosimilar Medicines | Fresenius Kabi Brasil Biopharma | |
|---|---|---|---|---|---|
| Provider | Sandozsandoz.comPublic | | | | |
| Founded | 1886 | 1978 | 2012 | — | |
| Sells To | Healthcare Providers, Hospitals, Retail | Enterprise, Government | — | — | |
| Pricing Model | B2B, Product Sales | Recurring, Software, Transactional | — | — | |
| Ownership | Public | Public | — | — |
Provider Sandozsandoz.comPublic
Founded 1886
Sells To Healthcare Providers, Hospitals, Retail
Pricing Model B2B, Product Sales
Ownership Public
Provider
Founded 1978
Sells To Enterprise, Government
Pricing Model Recurring, Software, Transactional
Ownership Public
Provider
Founded 2012
Sells To —
Pricing Model —
Ownership —
Provider
Founded —
Sells To —
Pricing Model —
Ownership —
Cristália's biological-ingredients operation, the first Brazilian pharmaceutical plant certified by Anvisa under CBPF standards.
EMS's hospital unit supplying medicines and solutions to hospitals and institutional healthcare buyers, reinforced by a 2026 injectables acquisition.
Oncology portfolio of chemotherapies and targeted therapies described as Brazil's largest chemotherapy offering.
Samsung BioepisSamsung Bioepis's biosimilars portfolio includes etanercept, adalimumab, infliximab, trastuzumab, and aflibercept products.
Cristália's biological-ingredients operation, the first Brazilian pharmaceutical plant certified by Anvisa under CBPF standards.
EMS's hospital unit supplying medicines and solutions to hospitals and institutional healthcare buyers, reinforced by a 2026 injectables acquisition.
Oncology portfolio of chemotherapies and targeted therapies described as Brazil's largest chemotherapy offering.
Samsung Bioepis's biosimilars portfolio includes etanercept, adalimumab, infliximab, trastuzumab, and aflibercept products.
Samsung BioepisTruxima is a rituximab biosimilar medicine used in blood cancer and autoimmune care.